Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

385

Participants

Timeline

Start Date

September 4, 2014

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
B-cell Malignancies
Interventions
DRUG

Zanubrutinib

Oral administration by capsule

Trial Locations (23)

3050

Peter MacCallum Cancer Centre, East Melbourne, Parkville

48109

University of Michigan, Ann Arbor

55901

Mayo Clinic, Rochester

77030

M.D. Anderson Cancer Center, Houston

85234

Banner MD Anderson Cancer Centre, Gilbert

Unknown

Concord Repatriation General Hospital, Concord

St George Hospital, Sydney

Westmead Hospital, Westmead

Princess Alexandra Hospital, Brisbane

Royal Hobart Hospital, Hobart

Monash Health, Clayton

Austin Health, Heidelberg

St Vincent's Hospital, Melbourne

Melbourne Health, Parkville

Sir Charles Gairdner Hospital, Nedlands

Policlinico S.Orsola Malpighi, AOU di Bologna, Bologna

Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milan

North Shore Hospital, Auckland

Dong-A University Medical Centre, Busan

Inje University Busan Paik Hospital, Busan

National Cancer Center, Goyang-si

Samsung Medical Center, Seoul

Derriford Hospital, Plymouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY